Add to ORKGPhase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderl
Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxici...
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However,...
Hodgkin lymphoma is the most frequent hematologic neoplasia in young adults. Most patients (> 80 %) ...
Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prog...
Approximately 20 % of all Hodgkin lym-phoma (HL) patients are older than 60 years and have a poor pr...
For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is m...
In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low i...
Background: In advanced age the prognosis of Hodgkin’s lymphoma (HL) is poor, but, as a consequence ...
Hodgkin Lymphoma HL ica be cured in the large majority of younger patients, but prognosis for o...
About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising s...
Purpose: The aim of this phase II study was to investi-gate the potential of the vincristine, epirub...
Introduction: Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy an...
Background In early stage classical Hodgkin lymphoma (cHL), reduction of treatment-associated toxici...
There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, d...
prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin’s lymphom
Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxici...
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However,...
Hodgkin lymphoma is the most frequent hematologic neoplasia in young adults. Most patients (> 80 %) ...
Approximately 20% of all Hodgkin lymphoma (HL) patients are older than 60 years and have a poor prog...
Approximately 20 % of all Hodgkin lym-phoma (HL) patients are older than 60 years and have a poor pr...
For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is m...
In advanced age the prognosis of Hodgkin's lymphoma (HL) is poor, but, as a consequence of the low i...
Background: In advanced age the prognosis of Hodgkin’s lymphoma (HL) is poor, but, as a consequence ...
Hodgkin Lymphoma HL ica be cured in the large majority of younger patients, but prognosis for o...
About 30% of all Hodgkin lymphoma (HL) patients are >= 60 years old. As lenalidomide has promising s...
Purpose: The aim of this phase II study was to investi-gate the potential of the vincristine, epirub...
Introduction: Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy an...
Background In early stage classical Hodgkin lymphoma (cHL), reduction of treatment-associated toxici...
There is a lack of contemporary prospective data examining the adriamycin, bleomycin, vinblastine, d...
prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin’s lymphom
Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxici...
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However,...
Hodgkin lymphoma is the most frequent hematologic neoplasia in young adults. Most patients (> 80 %) ...